OBJECTIVE: To examine the 12-month prevalence of psychotropic medication use among adolescents, and the match between mental disorder diagnoses and past-year antidepressant and stimulant use. METHOD: Data are from the National Comorbidity Survey-Adolescent Supplement (2002-2004), a nationally representative survey of 10,123 adolescents aged 13 to 18 years that assesses DSM-IV disorders using a fully structured diagnostic interview, a modified version of the World Health Organization Composite International Diagnostic Interview (CIDI). Rates of 12-month psychotropic medication use are stratified by respondent socio-demographic characteristics, and the distribution of 12-month DSM-IV CIDI disorders is estimated among past-12-month use of antidepressants and stimulants. RESULTS: During a 1-year period, 7.0% of adolescents used at least one psychotropic medication; these medications were most commonly antidepressants (3.9%), followed by stimulants (2.8%), anxiolytics (0.8%), antipsychotics (0.5%), and mood stabilizers (0.4%). Nearly three-quarters (74.1%) of adolescents with any past-year psychotropic medication use had at least one CIDI mental disorder, and many had disorders for which the specific medication class is clinically indicated. Among adolescents using antidepressants, 48.8% had a past-12-month depressive or anxiety disorder, and an additional 20.3% had a lifetime depressive or anxiety disorder. Nearly one-half (49.1%) of adolescents using stimulants met past-12-month attention-deficit/hyperactivity disorder (ADHD) criteria, and an additional 13.1% met lifetime criteria for ADHD. CONCLUSIONS: Most adolescents who are treated with psychotropic medications have one or more psychiatric disorders and many, albeit far from all, have mental disorders for which the specific medications are clinically indicated. Published by Elsevier Inc.
OBJECTIVE: To examine the 12-month prevalence of psychotropic medication use among adolescents, and the match between mental disorder diagnoses and past-year antidepressant and stimulant use. METHOD: Data are from the National Comorbidity Survey-Adolescent Supplement (2002-2004), a nationally representative survey of 10,123 adolescents aged 13 to 18 years that assesses DSM-IV disorders using a fully structured diagnostic interview, a modified version of the World Health Organization Composite International Diagnostic Interview (CIDI). Rates of 12-month psychotropic medication use are stratified by respondent socio-demographic characteristics, and the distribution of 12-month DSM-IV CIDI disorders is estimated among past-12-month use of antidepressants and stimulants. RESULTS: During a 1-year period, 7.0% of adolescents used at least one psychotropic medication; these medications were most commonly antidepressants (3.9%), followed by stimulants (2.8%), anxiolytics (0.8%), antipsychotics (0.5%), and mood stabilizers (0.4%). Nearly three-quarters (74.1%) of adolescents with any past-year psychotropic medication use had at least one CIDI mental disorder, and many had disorders for which the specific medication class is clinically indicated. Among adolescents using antidepressants, 48.8% had a past-12-month depressive or anxiety disorder, and an additional 20.3% had a lifetime depressive or anxiety disorder. Nearly one-half (49.1%) of adolescents using stimulants met past-12-month attention-deficit/hyperactivity disorder (ADHD) criteria, and an additional 13.1% met lifetime criteria for ADHD. CONCLUSIONS: Most adolescents who are treated with psychotropic medications have one or more psychiatric disorders and many, albeit far from all, have mental disorders for which the specific medications are clinically indicated. Published by Elsevier Inc.
Authors: T E Wilens; T J Spencer; J Biederman; K Girard; R Doyle; J Prince; D Polisner; R Solhkhah; S Comeau; M C Monuteaux; A Parekh Journal: Am J Psychiatry Date: 2001-02 Impact factor: 18.112
Authors: Julie Magno Zito; Daniel J Safer; Susan DosReis; James F Gardner; Karen Soeken; Myde Boles; Frances Lynch Journal: Pediatrics Date: 2002-05 Impact factor: 7.124
Authors: Mark L Wolraich; Charles J Wibbelsman; Thomas E Brown; Steven W Evans; Edward M Gotlieb; John R Knight; E Clarke Ross; Howard H Shubiner; Esther H Wender; Timothy Wilens Journal: Pediatrics Date: 2005-06 Impact factor: 7.124
Authors: Howard Abikoff; James McGough; Benedetto Vitiello; James McCracken; Mark Davies; John Walkup; Mark Riddle; Melvin Oatis; Laurence Greenhill; Anne Skrobala; John March; Pat Gammon; James Robinson; Robert Lazell; Donald J McMahon; Louise Ritz Journal: J Am Acad Child Adolesc Psychiatry Date: 2005-05 Impact factor: 8.829
Authors: Lisa A Cooper; Junius J Gonzales; Joseph J Gallo; Kathryn M Rost; Lisa S Meredith; Lisa V Rubenstein; Nae-Yuh Wang; Daniel E Ford Journal: Med Care Date: 2003-04 Impact factor: 2.983
Authors: Robert B Penfold; Christine Stewart; Enid M Hunkeler; Jeanne M Madden; Janet R Cummings; Ashli A Owen-Smith; Rebecca C Rossom; Christine Y Lu; Frances L Lynch; Beth E Waitzfelder; Karen J Coleman; Karen A Coleman; Brian K Ahmedani; Arne L Beck; John E Zeber; Gregory E Simon Journal: Curr Psychiatry Rep Date: 2013-12 Impact factor: 5.285
Authors: Meg H Zeller; Jennie G Noll; David B Sarwer; Jennifer Reiter-Purtill; Dana L Rofey; Amy E Baughcum; James Peugh; Anita P Courcoulas; Marc P Michalsky; Todd M Jenkins; Jennifer N Becnel Journal: J Pediatr Psychol Date: 2015-03-15
Authors: Ryan S Sultan; Christoph U Correll; Michael Schoenbaum; Marrisa King; John T Walkup; Mark Olfson Journal: J Child Adolesc Psychopharmacol Date: 2018-01-29 Impact factor: 2.576
Authors: Peggy L O'Brien; Cindy Parks Thomas; Dominic Hodgkin; Katharine R Levit; Tami L Mark Journal: Psychiatr Serv Date: 2014-11-17 Impact factor: 3.084
Authors: Robert B Penfold; Ella E Thompson; Robert J Hilt; Nadine Schwartz; Adelaide S Robb; Christoph U Correll; Douglas Newton; Kelly Rogalski; Marian F Earls; Robert A Kowatch; Arne Beck; Bobbi Jo H Yarborough; Stephen Crystal; Benedetto Vitiello; Kelly J Kelleher; Gregory E Simon Journal: J Am Acad Child Adolesc Psychiatry Date: 2021-05-04 Impact factor: 8.829